# ncmlsg.org > Nordic CML Study group ## Posts - [Symposium activities](https://ncmlsg.org/symposium-activities/): Overview Students look here! Advanced education in the Symposium - [Registration for symposium](https://ncmlsg.org/register-here-for-the-spring-symposium/): You may register at via this link to the NCMLSG education symposium, school and group meeting here. Most welcome! See also “Events” page. Registration to the event For those who want to become or stay members please also register for membership via this link. For technical reasons all previous members must register in the new system . https://ncmlsg.org/sign-in - [Membership registration](https://ncmlsg.org/register-as-a-member/):   Sign up for a user account for quicker registrations, and access member-only materials and updates. Getting started is simple: choose Register on the site, enter your email, and confirm it through the link we send you. Set a password, add your name, workplace, and role, and pick your communication preferences. The admin  manually approves your request, and you will receive confirmation once approved.  Already registered? Use Sign in. Forgot your password? Select Forgot password to get a reset link.If you need help at any point, reach out via the Contact page. Your information is only used for NCMLSG membership […] ## Pages - [Registration redirect](https://ncmlsg.org/registration-redirect/): Thanks for registering to our site! We’ve sent a confirmation email to your address. An administrator has been notified and will review your request. You’ll receive another email once your account is approved (or declined). - [Forum](https://ncmlsg.org/community/) - [Studies](https://ncmlsg.org/studies/): Studies from the group Previous Main Studies Ongoing STUDIES (1) Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009 May 7;113(19):4497-504.NordCML001 (2) Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A, et al. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011 Sep 22;118(12):3228-35. NordCML002 (3) Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila […] - [News](https://ncmlsg.org/news/): REIMBURSEMENT FORM/Nordic CML Study Group In order to receive reimbursement for expenses regarding participation in NCMLSG meetings, please use this form as an enclosure when submitting the original receipts. Preferably fill in the form with a computer or a typewriter. Attachments: NCMLSG_reimbursement.doc - [Bylaws](https://ncmlsg.org/bylaws/): Rules of procedure for Nordic Chronic Myeloid Leukemia Study Group/NCMLSG These rules of procedure (bylaws) are laid down by the Members of the Nordic Chronic Myeloid Leukemia Study Group (hereinafter referred to as the “Organisation”). The rules become effective on November 1st 2006 Purpose of the Organisation The purpose of the Organisation is the creation of a high quality group of excellence with interest in the treatment and biology of Chronic Myeloid Leukemia (hereinafter referred to as the “Field”).  The Organisation’s aims and goals Article 1 The Organisation aims to improve treatment and research within the Field in the Nordic […] - [Contact](https://ncmlsg.org/contact/): Contact Us We’re Ready, Let’s Talk. Contact Info Address​ St Olavs Hospital Dept of Hematology PB8250 Sluppen NO-7006 Trondheim Norway Email Us henrik.hjorth-hansen@ntnu.no Call Us +47 72 82 51 76 - [Publications](https://ncmlsg.org/publications/): Publications from the group 2023 Warfvinge R, Geironson Ulfsson L, Dhapola P, Safi F, Sommarin MNE, Soneji S, Hjorth-Hansen H, Mustjoki S, Richter J, Thakur RK, Karlsson G. Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response. E-life https://doi.org/10.1101/2023.08.16.553504; Huuhtanen J, Adnan-Awad S, Theodoropoulos J, Forstén S, Warfvinge R, Dufva O, Bouhlal J, Dhapola P, Duàn H, Laajala E, Kasanen T, Klievink J, Ilander M, Jaatinen T, Olsson-Strömberg U, Hjorth-Hansen H, Burchert A, Karlsson G, Kreutzman A, Lähdesmäki H, Mustjoki S. Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor […] - [Guidelines-education](https://ncmlsg.org/guidelines/): Guidelines DK_Cml_Vejledning ELN recommendations for treating CML 2020 ELN recommendations for treating CML 2025 Kronisk myelogen leukemi (KML)_ Norsk Nasjonal faglig retningslinje.pdf​ Nationellt-vardprogram-kronisk-myeloisk-leukemi-kml_SWE Useful links Blodkreftforeningen – Norge Chronic Myeloid Leukaemia (CML) – Leukemia Care Chronic myeloid leukemia ELN LeukemiaNet Nationellt kvalitetsregister för KML The International CML Foundation - [About](https://ncmlsg.org/about/): About us Our aim We aim is to cure CML patients without allogeneic transplantation and improve treatment of CML . Our group consists of scientists, clinicians and nurses interested in CML. We work all over the Nordic region, mainly at University Hospitals but also hematologists working in other hospitals are active in our group. We meet twice a year (generally April and November). Our activities have been supported by partners in pharmaceutical industry, and we regard this cooperation as an essential element for progress We will pursue our aim by conducting clinical trials and attached to such trials address scientific […] - [Home](https://ncmlsg.org/): Nordic CML Study Group – Advancing CML Care News Events Our events bring together clinicians, nurses, scientists, and partners to share the latest in CML care and research. Explore the calendar, learn more about each session, and secure your spot with quick registration. Our aim We aim is to cure CML patients without allogeneic transplantation and improve treatment of CML . Our group consists of scientists, clinicians and nurses interested in CML. We work all over the Nordic region, mainly at University Hospitals but also hematologists working in other hospitals are active in our group. We meet twice a year […] - [Password Reset](https://ncmlsg.org/password-reset/): [ultimatemember_password] - [Account](https://ncmlsg.org/account/): [ultimatemember_account] - [Logout](https://ncmlsg.org/logout/) - [Members](https://ncmlsg.org/members-2/): [ultimatemember form_id=”2583″] - [Register](https://ncmlsg.org/register/): [ultimatemember form_id=”2580″] - [Login](https://ncmlsg.org/login/): [ultimatemember form_id=”2581″] - [User](https://ncmlsg.org/user/): [ultimatemember form_id=”2582″] - [Members](https://ncmlsg.org/members/) - [Privacy Policy](https://ncmlsg.org/privacy-policy/): We care about the privacy of our users, and this privacy policy explains how we collect and use information about visitors to our website. The policy contains information you are entitled to when data is collected from our website (Section 19 of the Personal Data Act), as well as general information about how we process personal data (Section 18, first paragraph of the Personal Data Act). Company name: Nordic CML Study group (NCMLSG)Address: St Olavs Hospital Dept of Hematology PB8250 Sluppen NO-7006 Trondheim NorwayContact us: henrik.hjorth-hansen@ntnu.no What Personal Data We Collect and Why – Web Analytics & Cookies As part […] [comment]: # (Generated by Hostinger Tools Plugin)